08:54 AM EDT, 09/12/2024 (MT Newswires) -- Kazia Therapeutics ( KZIA ) said Thursday it has executed a deal with QIMR Berghofer Medical Research Institute, an Australian cancer research center, to receive a license for certain intellectual property to develop any drugs or product candidates within the PI3K inhibitor class in combination with immunotherapy or PARP inhibitors.

Financial terms weren't disclosed.

The company first partnered with the cancer research center in December 2022, Kazia added.

Shares of the company were up 3% in recent Thursday premarket activity.

Price: 0.3780, Change: +0.01, Percent Change: +3.53